Request for Nominations, 8287-8288 [2018-03853]
Download as PDF
<![CDATA[
8287
Federal Register / Vol. 83, No. 38 / Monday, February 26, 2018 / Notices
submitting information to confirm their
designations remain appropriate. We
use the information to ensure their
designations remain appropriate.
Description of Respondents:
Respondents to this information
collection include rendering facilities,
feed manufacturers, livestock feeders,
and foreign governments seeking
designation under § 589.2001(f).
In the Federal Register of November
3, 2017 (82 FR 51279), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. We received four
comments, which were not responsive
to the four collection of information
topics solicited, and therefore will not
be discussed in this document.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
21 CFR section
Number of
records per
recordkeeper
Average
burden per
recordkeeping
Total annual
records
Total hours
589.2001(c)(2)(ii), maintain written procedures .................
589.2001(c)(2)(vi) and (c)(3)(i), maintain records .............
589.2001(c)(3)(i)(A) and (B), certification or documentation from the supplier .....................................................
50
175
1
1
50
175
20
20
1,000
3,500
175
1
175
26
4,550
Total ............................................................................
..........................
........................
........................
........................
9,050
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Except where otherwise noted, this
estimate is based on our estimate of the
number of facilities affected by the final
rule entitled ‘‘Substances Prohibited
From Use in Animal Food or Feed’’
published in the Federal Register of
April 25, 2008 (73 FR 22720 at 22753).
The estimated recordkeeping burden is
derived from Agency resources and
discussions with affected industry. Our
regulations require the maintenance of
certain written procedures if cattle not
inspected and passed for human
consumption are to be rendered for use
in animal feed. The recordkeeping
burden associated with the requirement
to maintain written procedures
(§ 589.2001(c)(2)(ii)) will apply to only
those renderers that choose to render for
use in animal feed cattle not inspected
and passed for human consumption.
The recordkeeping requirement in
§ 589.2001(c)(2)(vi) will apply to the
limited number of renderers that will
handle CMPAF. We estimate that the
recordkeeping burden associated with
§ 589.2001(c)(3)(i) would apply to the
balance of the rendering firms not
handling CMPAF. Table 1 also reflects
the estimated 26 hours each renderer
will need to satisfy the requirement in
§ 589.2001(c)(3)(i)(A) and (B) under
which renderers must maintain records
from their supplier, certifying that
materials provided were free of CMPAF.
TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1
589.2001(f); request for designation ..................................
589.2001(f); response to request for review by FDA ........
daltland on DSKBBV9HB2PROD with NOTICES
1 There
Number of
responses per
respondent
Number of
respondents
21 CFR section
1
1
Average
burden per
response
Total annual
responses
1
1
1
1
Total hours
80
26
80
26
are no capital costs or operating and maintenance costs associated with this collection of information.
Our estimate of the reporting burden
for designation under § 589.2001(f) is
based on estimates in the final rule
entitled ‘‘Substances Prohibited From
Use in Animal Food or Feed’’ published
in the Federal Register of April 25,
2008, our experience, and the average
number of requests for designation
received in the past 3 years. The
reporting burden for § 589.2001(f) is
minimal because requests for
designation are seldom submitted. Since
2009, we have received two requests for
designation. In the last 3 years, we have
not received any new requests for
designation; therefore, we estimate that
one or fewer requests for designation
will be submitted annually. Although
we have not received any new requests
for designation in the last 3 years, we
believe these information collection
provisions should be extended to
provide for the potential future need of
VerDate Sep<11>2014
17:58 Feb 23, 2018
Jkt 244001
a foreign government to request
designation under § 589.2001(f). Table
2, row 1, presents the expected burden
of requests for designation. Countries
designated under § 589.2001(f) are
subject to review by FDA to ensure that
their designation remains appropriate.
We assume a country’s response to a
request for review will take about one
third the time and effort of a request for
designation. Table 2, row 2, presents the
expected burden of a request for review.
The burden for this information
collection has not changed since the last
OMB approval.
Dated: February 21, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018–03848 Filed 2–23–18; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Request for Nominations
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Request for Nominations to the
Centers for Disease Control and
Prevention (CDC)/HRSA Advisory
Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment.
AGENCY:
HRSA is seeking nominations
of four qualified candidates to be
considered for appointment as members
of the CDC/HRSA Advisory Committee
on HIV, Viral Hepatitis and STD
Prevention and Treatment (Committee).
The Committee consists of 18 public
SUMMARY:
E:\FR\FM\26FEN1.SGM
26FEN1
8288
Federal Register / Vol. 83, No. 38 / Monday, February 26, 2018 / Notices
members, including two co-chairs. The
Committee membership maintains a
balance of diverse experiences and
expertise. Those requesting
consideration require expertise in areas
such as: Public health; epidemiology;
laboratory practice; immunology;
infectious diseases; behavioral health
and science including, but not limited
to opioid use and related expertise;
health education; healthcare delivery;
state health programs; clinical care;
preventive health; medical education;
health services and clinical research;
and healthcare financing. In addition,
people living with HIV and affected
populations as well as individuals
employed by state and local health and
education agencies, HIV/viral hepatitis/
STD community-based organizations,
and the ethics or religious community
are encouraged to submit nomination
packages for consideration. Current
federal employees will not be
considered.
Written nominations for
membership to the Committee must be
received on or before May 30, 2018.
Packages received after this time will
not be considered for the current
membership cycle. (See SUPPLEMENTARY
INFORMATION, below, for required
documentation.)
DATES:
Submit your electronic
nomination package by electronic mail
to CHACAdvisoryComm@hrsa.gov.
FOR FURTHER INFORMATION CONTACT: CDR
Holly Berilla, HRSA, HIV/AIDS Bureau
by email at CHACAdvisoryComm@
hrsa.gov or by telephone at (301) 443–
9965. A copy of the Committee Charter
and background information can be
obtained by accessing the Advisory
Committee website at https://
www.cdc.gov/maso/facm/
facmchachspt.html.
ADDRESSES:
The CDC/
HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and
Treatment was established under
Section 222 of the Public Health Service
(PHS) Act, [42 U.S.C. Section 217a], as
amended.
The purpose of the Committee is to
advise the Secretary, HHS; the Director,
CDC; and the Administrator, HRSA
regarding objectives, strategies, policies,
and priorities for HIV, viral hepatitis,
and other STD prevention and treatment
efforts including surveillance of HIV
infection, AIDS, viral hepatitis, and
other STDs, and related behaviors;
epidemiologic, behavioral, health
services, and laboratory research on
HIV, viral hepatitis, and other STDs;
identification of policy issues related to
HIV/viral hepatitis/STD professional
daltland on DSKBBV9HB2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:58 Feb 23, 2018
Jkt 244001
education, patient healthcare delivery,
and prevention services; Agency
policies about prevention of HIV, viral
hepatitis and other STDs, treatment,
healthcare delivery, and research and
training; strategic issues influencing the
ability of CDC and HRSA to fulfill their
missions of providing prevention and
treatment services; programmatic efforts
to prevent and treat HIV, viral hepatitis,
and other STDs; and support to the
Agencies in their developoment of
responses to emerging health needs
related to HIV, viral hepatitis, and other
STDs.
Members selected will be considered
special government employees (SGEs)
and may be invited to serve four (4) year
terms. SGEs are eligible to receive a
stipend and reimbursement for per diem
and any travel expenses incurred for
attending Committee meetings, as
authorized by section 5 U.S.C. 5703 for
persons employed intermittently in
government service. Approved
nominees will be invited to serve during
calendar year 2019.
The following information must be
included in the electronic nomination
package for each individual to be
considered for nomination: (1) A
statement clearly indicating the name
and affiliation of the nominee, the basis
for the nomination (i.e., specific
attributes such as experience, education,
current affiliations, positions, etc.), and
that the nominee is willing to serve as
a member of the Committee; (2) the
nominee’s name, address, and daytime
telephone number and the home/or
work address, and email address; and
(3) a current copy of the nominee’s
curriculum vitae. Nomination packages
may be summited directly by the
individual being nominated or by the
person/organization recommending the
candidate.
HHS is required to ensure that the
membership of the Committee is
balanced in terms of points of view
represented. Every effort is made to
ensure that individuals from a broad
representation of geographic areas,
gender, ethnic and minority groups, as
well as individuals with disabilities are
given consideration for membership and
therefore, HHS encourages nominations
of qualified candidates from these
groups. HHS also encourages geographic
diversity in the composition of the
Committee. Appointments shall be
made without discrimination based on
age, ethnicity, gender, sexual
orientation, and cultural, religious, or
socioeconomic status.
Individuals who are selected for
appointment will be required to provide
detailed information regarding their
financial holdings, consultancies, and
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
research grants or contracts. Disclosure
of this information is necessary in order
to determine if the selected candidate is
involved in any activity that may pose
a potential conflict with the official
duties to be performed as a member of
the Committee.
Amy McNulty,
Acting Director, HRSA, Division of the
Executive Secretariat.
[FR Doc. 2018–03853 Filed 2–23–18; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Service
Administration
Advisory Commission on Childhood
Vaccines
Health Resources and Service
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, notice
is hereby given that a meeting is
scheduled for the Advisory Commission
on Childhood Vaccines (ACCV). This
meeting will be open to the public.
Information about the ACCV and the
agenda for this meeting can be obtained
by accessing the following website:
https://www.hrsa.gov/
advisorycommittees/childhoodvaccines/
index.html.
SUMMARY:
The meeting will be held on
March 8, 2018, at 10:00 a.m. ET.
ADDRESSES: This meeting will be held
via Adobe Connect meeting and
conference call. This is not an in-person
meeting. The public can join the
meeting by:
1. (Audio Portion) Calling the
conference phone number (800) 988–
0218 and providing the following
information:
Leader Name: Dr. Narayan Nair.
Password: 9302948.
2. (Visual Portion) Connecting to the
ACCV Adobe Connect Meeting using the
following URL: https://
hrsa.connectsolutions.com/accv/.
Participants should call and connect 15
minutes prior to the meeting in order for
logistics to be set up. If you have never
attended an Adobe Connect meeting,
please test your connection using the
following URL: https://
hrsa.connectsolutions.com/common/
help/en/support/meeting_test.htm and
get a quick overview by following URL:
https://www.adobe.com/go/connectpro_
overview.
DATES:
E:\FR\FM\26FEN1.SGM
26FEN1
]]>Agencies
[Federal Register Volume 83, Number 38 (Monday, February 26, 2018)]
[Notices]
[Pages 8287-8288]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-03853]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Request for Nominations
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Request for Nominations to the Centers for Disease Control and
Prevention (CDC)/HRSA Advisory Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment.
-----------------------------------------------------------------------
SUMMARY: HRSA is seeking nominations of four qualified candidates to be
considered for appointment as members of the CDC/HRSA Advisory
Committee on HIV, Viral Hepatitis and STD Prevention and Treatment
(Committee). The Committee consists of 18 public
[[Page 8288]]
members, including two co-chairs. The Committee membership maintains a
balance of diverse experiences and expertise. Those requesting
consideration require expertise in areas such as: Public health;
epidemiology; laboratory practice; immunology; infectious diseases;
behavioral health and science including, but not limited to opioid use
and related expertise; health education; healthcare delivery; state
health programs; clinical care; preventive health; medical education;
health services and clinical research; and healthcare financing. In
addition, people living with HIV and affected populations as well as
individuals employed by state and local health and education agencies,
HIV/viral hepatitis/STD community-based organizations, and the ethics
or religious community are encouraged to submit nomination packages for
consideration. Current federal employees will not be considered.
DATES: Written nominations for membership to the Committee must be
received on or before May 30, 2018. Packages received after this time
will not be considered for the current membership cycle. (See
SUPPLEMENTARY INFORMATION, below, for required documentation.)
ADDRESSES: Submit your electronic nomination package by electronic mail
to [email protected].
FOR FURTHER INFORMATION CONTACT: CDR Holly Berilla, HRSA, HIV/AIDS
Bureau by email at [email protected] or by telephone at (301)
443-9965. A copy of the Committee Charter and background information
can be obtained by accessing the Advisory Committee website at https://www.cdc.gov/maso/facm/facmchachspt.html.
SUPPLEMENTARY INFORMATION: The CDC/HRSA Advisory Committee on HIV,
Viral Hepatitis and STD Prevention and Treatment was established under
Section 222 of the Public Health Service (PHS) Act, [42 U.S.C. Section
217a], as amended.
The purpose of the Committee is to advise the Secretary, HHS; the
Director, CDC; and the Administrator, HRSA regarding objectives,
strategies, policies, and priorities for HIV, viral hepatitis, and
other STD prevention and treatment efforts including surveillance of
HIV infection, AIDS, viral hepatitis, and other STDs, and related
behaviors; epidemiologic, behavioral, health services, and laboratory
research on HIV, viral hepatitis, and other STDs; identification of
policy issues related to HIV/viral hepatitis/STD professional
education, patient healthcare delivery, and prevention services; Agency
policies about prevention of HIV, viral hepatitis and other STDs,
treatment, healthcare delivery, and research and training; strategic
issues influencing the ability of CDC and HRSA to fulfill their
missions of providing prevention and treatment services; programmatic
efforts to prevent and treat HIV, viral hepatitis, and other STDs; and
support to the Agencies in their developoment of responses to emerging
health needs related to HIV, viral hepatitis, and other STDs.
Members selected will be considered special government employees
(SGEs) and may be invited to serve four (4) year terms. SGEs are
eligible to receive a stipend and reimbursement for per diem and any
travel expenses incurred for attending Committee meetings, as
authorized by section 5 U.S.C. 5703 for persons employed intermittently
in government service. Approved nominees will be invited to serve
during calendar year 2019.
The following information must be included in the electronic
nomination package for each individual to be considered for nomination:
(1) A statement clearly indicating the name and affiliation of the
nominee, the basis for the nomination (i.e., specific attributes such
as experience, education, current affiliations, positions, etc.), and
that the nominee is willing to serve as a member of the Committee; (2)
the nominee's name, address, and daytime telephone number and the home/
or work address, and email address; and (3) a current copy of the
nominee's curriculum vitae. Nomination packages may be summited
directly by the individual being nominated or by the person/
organization recommending the candidate.
HHS is required to ensure that the membership of the Committee is
balanced in terms of points of view represented. Every effort is made
to ensure that individuals from a broad representation of geographic
areas, gender, ethnic and minority groups, as well as individuals with
disabilities are given consideration for membership and therefore, HHS
encourages nominations of qualified candidates from these groups. HHS
also encourages geographic diversity in the composition of the
Committee. Appointments shall be made without discrimination based on
age, ethnicity, gender, sexual orientation, and cultural, religious, or
socioeconomic status.
Individuals who are selected for appointment will be required to
provide detailed information regarding their financial holdings,
consultancies, and research grants or contracts. Disclosure of this
information is necessary in order to determine if the selected
candidate is involved in any activity that may pose a potential
conflict with the official duties to be performed as a member of the
Committee.
Amy McNulty,
Acting Director, HRSA, Division of the Executive Secretariat.
[FR Doc. 2018-03853 Filed 2-23-18; 8:45 am]
BILLING CODE 4165-15-P
